Drug Trial Radar · NCT04590326
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
612
Planned (sponsor's estimate)
Start
Dec 8, 2020
Primary completion
Nov 8, 2028
Study completion Nov 8, 2028
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Oct 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main purposes of this study are to: * Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus * Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2. The study is looking at several other research questions, including: * Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab * How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab * How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood * To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer
Conditions
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- Endometrial Cancer
Interventions
REGN5668Drug
Administer per the protocol
CemiplimabDrug
Administer per the protocol
UbamatamabDrug
Administer per the protocol
SarilumabDrug
Administer per the protocol
Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]Drug
Administer per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLT)Time frame: 42 days
- Incidence of DLTsTime frame: 21 days post combination administration
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Through study completion, up to 5 years
- Incidence of Serious Adverse Events (SAEs)Time frame: Through study completion, up to 5 years
- Incidence of deathsTime frame: Through study completion, up to 5 years
- Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])Time frame: Through study completion, up to 5 years
- Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamabTime frame: Through study completion, up to 5 years
- Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)Time frame: Through study completion, up to 5 years
Locations
28 sites in 5 countries. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
The City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California · Recruiting
Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
H. Lee Moffitt Cancer Center
Tampa, Florida · Completed
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute Brookline Avenue
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
The Ohio State University Wexner Medical Center
Columbus, Ohio · Recruiting
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Seattle Cancer Care Alliance at South Lake Union - G3630
Seattle, Washington · Recruiting
Universitair Ziekenhuis Leuven
Leuven, Vlaams-Brabant, Belgium · Recruiting
AC Camargo Cancer Center, Fundacao Antonio Prudente
São Paulo, Brazil · Recruiting
Centro de Pesquisa em Oncologia PUCRS
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Fundacao Pio XII - Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil · Recruiting
Unimed Sorocaba
Sorocaba, São Paulo, Brazil · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
Hopital Lyon Sud
Pierre-Bénite, Auvergne-Rhône, France · Recruiting
Centre Georges Francois Leclerc
Dijon, Bourgogne-Franche-Comté, France · Recruiting
Institut Bergonie
Bordeaux, New Aquitaine, France · Recruiting
Centre Francois Baclesse (CFB)
Caen, Normandy, France · Recruiting
Institut Catala dOncologia Girona
Girona, Spain · Recruiting
Ciudad Universitaria
Madrid, Spain · Recruiting
Hospital Universitario Fundacion Jimenez
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
Madrid, Spain · Recruiting
Hospital Clinico Universitario Santiago de Compostela
Santiago de Compostela, A Coruna, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.